Recent Advances in Hemophilia Gene Therapy
author
Abstract:
Heterogeneous loss of function mutations at F8 and F9 genes causes X-linked recessive bleeding disorders, hemophilia A (HA) and hemophilia B (HB), respectively. HA is clinically indistinguishable from HB and accounts for more than 80% of hemophilia cases; the former affects 1/5000 and the latter 1/25000 male births worldwide. In Iran, it is estimated that around 4300 HA and 900 HB patients are under care. The standard care for hemophilia patients is lifelong on demand or prophylactic factor replacement therapy. However, the complications such as arthropathies in severe form of the disease and viral infections are not uncommon. The cost of prophylactic treatment is high and not affordable in developing countries. The annual cost of hemophilia treatment in Iran is not predictable, but it is estimated to be around 50,000-60,000 US dollars/patient...
similar resources
Barriers and recent advances in non-viral vectors targeting the lungs for cystic fibrosis gene therapy
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in CFTR genes that affect chloride ion channel. The CF is a good nominee for gene therapy as the asymptomatic carriers are phenotypically normal, and the desired cells are accessible for vector delivery. Gene therapy shows promising effects involving the correction of gene or replacement of the mutant gene with the func...
full textAdvances in Overcoming Immune Responses following Hemophilia Gene Therapy.
Both Clinical trials and pre-clinical experiments for hemophilia gene therapy showed that it is important to overcome potential immune responses against gene transfer vectors and/or transgene products to ensure the success of gene therapy. Recently various approaches have been investigated to prevent or modulate such responses. Gene transfer vectors have been specifically engineered and immunos...
full textRecent advances in esophageal cancer gene therapy.
In recent years, the development of gene therapy systems as new treatment or prevention strategies for various malignant diseases has been explored. Based on the genetic background of esophageal cancer, several molecular therapies have been developed. In this article, we review p53 genetic alterations and angiogenesis in esophageal cancer. Our recent clinical results from a phase I/II study of ...
full textGene therapy for hemophilia.
Hemophilia is an X-linked inherited bleeding disorder consisting of two classifications, hemophilia A and hemophilia B, depending on the underlying mutation. Although the disease is currently treatable with intravenous delivery of replacement recombinant clotting factor, this approach represents a significant cost both monetarily and in terms of quality of life. Gene therapy is an attractive al...
full textGene therapy for hemophilia.
Hemophilia A and B are X-chromosome linked recessive bleeding disorders that result from a deficiency in factor VIII (FVIII) and factor IX (FIX) respectively. Though factor substitution therapy has greatly improved the lives of hemophiliac patients, there are still limitations to the current treatment that have triggered interest in alternative treatments by gene therapy. Significant progress h...
full textRecent Advances and Improvements in the Biosafety of Gene Therapy
1.1 Overview of gene therapy Progress in understanding the cellular and molecular bases of human health and disease in recent decades has spawned research in the fields of regenerative medicine and gene therapy. These novel approaches to medical treatments offer new possibilities of mitigating, and even curing, a plethora of medical conditions ranging from rare inherited monogenic disorders, me...
full textMy Resources
Journal title
volume 23 issue 1
pages 7- 8
publication date 2019-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023